Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
You may also be interested in...
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.